Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA; AIDS Clinical Trials Group Study A5202 Team.

J Infect Dis. 2011 Oct 15;204(8):1191-201. doi: 10.1093/infdis/jir505.

2.

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC; AIDS Clinical Trials Group Study A5202 Team.

Ann Intern Med. 2011 Apr 5;154(7):445-56. doi: 10.7326/0003-4819-154-7-201104050-00316. Epub 2011 Feb 14.

3.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES; AIDS Clinical Trials Group Study A5202 Team.

N Engl J Med. 2009 Dec 3;361(23):2230-40. doi: 10.1056/NEJMoa0906768. Epub 2009 Dec 1.

4.

Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.

Grant P, Taylor J, Cain P, Short W, Gallant J, Farthing C, Thal G, Coakley E, Zolopa A.

Clin Infect Dis. 2009 Mar 1;48(5):680-2. doi: 10.1086/597008.

PMID:
19191657
5.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.

Wilkin TJ, McKinnon JE, DiRienzo AG, Mollan K, Fletcher CV, Margolis DM, Bastow B, Thal G, Woodward W, Godfrey C, Wiegand A, Maldarelli F, Palmer S, Coffin JM, Mellors JW, Swindells S.

J Infect Dis. 2009 Mar 15;199(6):866-71. doi: 10.1086/597119.

6.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW; AIDS Clinical Trials Group 5201 Study Team.

JAMA. 2006 Aug 16;296(7):806-14.

PMID:
16905786
7.

Further information on the administration of h2-receptor antagonists with atazanavir.

Agarwala S, Thal G, Nettles R, Bertz R.

J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):516. No abstract available.

PMID:
16763527
8.

Exacerbation or unmasking of focal neurologic deficits by sedatives.

Thal GD, Szabo MD, Lopez-Bresnahan M, Crosby G.

Anesthesiology. 1996 Jul;85(1):21-5; discussion 29A-30A.

PMID:
8694368
9.

Acute, subacute, and chronic histologic effects of simulated aspiration of a 0.7% sucralfate suspension in rats.

Shepherd KE, Faulkner CS, Thal GD, Leiter JC.

Crit Care Med. 1995 Mar;23(3):532-6.

PMID:
7874906
10.

Pharmacodynamics of vecuronium and atracurium in the obese surgical patient.

Weinstein JA, Matteo RS, Ornstein E, Schwartz AE, Goldstoff M, Thal G.

Anesth Analg. 1988 Dec;67(12):1149-53.

PMID:
2904232
11.

Medical school to residency.

Thal GD.

JAMA. 1988 Sep 2;260(9):suppl 8. No abstract available.

PMID:
3404618
12.
13.

Immunological analysis of chick notochord and cartilage matrix development with antisera to cartilage matrix macromolecules.

Oettinger HF, Thal G, Sasse J, Holtzer H, Pacifici M.

Dev Biol. 1985 May;109(1):63-71.

PMID:
3921417
14.

Supplemental Content

Loading ...
Support Center